GPPL's port-concession extension remains conditional, not confirmed Logistics & Transport
Gujarat Pipavav Port's concession extension beyond its Sept 2028 expiry is still not secured: the Gujarat Maritime Board's August 2026 'comfort letter' only permits GPPL to process an extension proposal, not approval. GPPL must submit a full performance record and capex/investment business plan within 90 days — by roughly Nov 24, 2026 — before the board decides. No submission or GMB decision has been confirmed yet, so the open claim stands unresolved.
Vadilal sets Oct 27 EGM to vote on revised related-party distribution pact FMCG
Following the Oct 1 lapse of its 10-year distribution agreement with related party Vadilal Enterprises Ltd (VEL) for lack of shareholder approval, Vadilal's board approved a revised 12-month pact (Nov 2026-Oct 2027) and scheduled an Oct 27 EGM to vote on it. Sources disagree on VEL's share of Vadilal's revenue (~79% vs ~92%), a disputed figure that itself underscores how dependent Vadilal is on this one distribution relationship. Shareholder approval is not yet secured.
Zensar's TMT/healthcare client-exit warning remains unresolved pending Q3 FY27 results Information Technology
No Q3 FY27 results exist yet to test management's warning of continued client exits in TMT and healthcare/life-sciences verticals. The most recent reported quarter (Q1 FY27) still shows TMT revenue down 9.1% QoQ / 28.0% YoY and HLS down 3.8% QoQ / 8.7% YoY in constant currency — consistent with, but not yet a resolution of, that forward-looking risk against the headline deal wins.
IKS Health closes ~$557M TruBridge acquisition, raises stake in IKS WWMG Healthcare & Hospitals
IKS Health completed its roughly $557M acquisition of TruBridge via syndicated financing, alongside FY26 revenue growth of 20% and a 48% jump in profit after tax; it separately raised its stake in IKS WWMG MSO LLC to 63.49%. The debt-funded deal is a real step-up in scale, though it also adds leverage to what was previously an asset-light model — worth tracking as integration proceeds.
Ajanta Pharma's Paithan plant FDA inspection closes clean (VAI status) Pharmaceuticals
The US FDA's April 2026 inspection of Ajanta Pharma's Paithan facility, which had raised a five-observation Form-483, has closed with Voluntary Action Indicated (VAI) status — meaning no regulatory or administrative action is required, with any corrective steps taken voluntarily. This resolves the earlier regulatory overhang cleanly.